A strategy to obtain a fully orthogonal estrogen-receptor-based gene switch responsive to molecules with acceptable pharmacological properties is presented. From a series of tetrahydrofluorenonesactive on the wild-type estrogen receptor (ER) an inactive analogue ischosen as a new lead compound. Coevolution of receptor mutants andligands leads to an ER-based gene switch suitable for studies in animalmodels.
